5th International Conference on Cardiomyopathy in Children

American College of Cardiology Conference Center | Washington D.C.
March 3 – March 4, 2021

Wednesday, March 3, 2021

7:30-8:00 am  Breakfast

8:00-8:45 am  Welcome and Overview
  • Lisa Yue and Steven Lipshultz, MD

8:45-10:45 am  Dilated Cardiomyopathy
  Session Leaders: Steve Lipshultz, MD, Daphne Hsu, MD, Paul Kantor, MBBCh, MSc
  • How effectively do we currently risk stratify and tailor medical therapy for DCM?
    Daphne Hsu, MD
  • Which new drug therapies are under investigation for DCM?
    Robert Shaddy, MD
  • When and how does dilated cardiomyopathy recover?
    Melanie Everitt, MD
  • How do we improve quality and maximize value in the care of dilated cardiomyopathy?
    Kimberly Lin, MD
  • Point Counterpoint: How should we design research studies on dilated cardiomyopathy?
    o Observational studies are the most useful approach.
      Bill Mahle, MD
    o Clinical trials are the most useful approach.
      Christopher Almond, MD, MPH
  • FDA perspective on approval of clinical trials.
    Lynn Yao, MD
  • General discussion and summary

10:45-11:00 am  Coffee Break
11:00-12:15 pm  Hypertrophic Cardiomyopathy  
Session Leaders: Charlie Canter, MD, Steve Colan, MD, Robert Weintraub, MBBS

- What are the differences between non-sarcomeric versus sarcomeric HCM and should they have their own management scheme?  
  Anne Murphy, MD

- Are P-G+ normal, diseased, or somewhere in between? / Role of genetic testing in clinical management?  
  Carolyn Ho, MD

- How should pediatric HCM be defined?  
  Steven Colan, MD

- What is the optimal imaging strategy for pediatric HCM: echo, MRI, or a hybrid approach? /What is the optimal evaluative or surveillance protocol for pediatric HCM, and the minimum dataset for ongoing clinical care?  
  Elfriede Pahl, MD

- How should HCM diagnosed in infancy be evaluated and managed?  
  Charlie Canter, MD

- Indications for surgical relief of LV outflow obstruction.  
  Robert Weintraub, MBBS

- Guided Discussion

12:15-1:15 pm  Lunch

1:15-2:25 pm  Hypertrophic Cardiomyopathy Continued  
Session Leaders: Charlie Canter, MD, Steve Colan, MD, Robert Weintraub, MBBS

- What is the optimal management strategy to minimize sudden death in children with HCM?  
  Juan Kaski, MD

- Debate: the pros and cons of pediatric HCM±ICD participation in competitive athletics  
  George Van Hare, MD and Jeffrey Kim, MD

- The epidemiology and global burden of hypertrophic cardiomyopathy  
  Paul Barach, MD

2:25-2:40 pm  Afternoon Break

2:40-4:40 pm  Genetics of Cardiomyopathy  
Session Leaders: Wendy Chung, MD, PhD, Shelley Miyamoto, MD, Stephanie Ware, MD, PhD

- Breaking News: Genetics of the primary cardiomyopathies.  
  Stephanie Ware, MD, PhD

- The CCF registry: providing the infrastructure for future pediatric cardiomyopathy research.  
  Wendy Chung, MD, PhD
• Update on gene-directed therapy for primary cardiomyopathies.
  Anjali Owens, MD
• Which new gene therapies are under investigation?
  Elizabeth McNally, MD, PhD
• Debate: Pros and cons of genetic testing.
  Erin Miller, MS, GSC and Benjamin Helm, MS, GSC
• General discussion and summary
• The clinical utility of genetic testing in pediatric cardiomyopathy.
  Andrew Landstrom, MD, PhD
• Panel Q&A

4:40-5:00 pm   Next Steps
5:00 pm   Dinner and Presentation by Jerrica Mathis

Thursday, March 4, 2021

8:00-8:30 am   Breakfast

8:30-10:30 am   Restrictive Cardiomyopathy
  Session Leaders: Joseph Rossano, MD, Michael Burch MB, Ch B, MRCP, MSc
  • Overview of current knowledge.
    Susan Denfield, MD
  • Risk stratification in RCM.
    Michael Burch MB, Ch B, MRCP, MSc
  • Secondary causes of RCM.
    Yuk Law, MD
  • Medical therapy for diastolic dysfunction: right around the corner or waiting for Godot?
    Paul Kantor, MBBCh, MSc
  • Moderated panel discussion
    o Moderators
      Michael Burch MB, Ch B, MRCP, MSc, Joseph Rossano, MD
    o Panel
      Robert Weintraub, MB BS, Susan Denfield, MD, Jeff Towbin, MD, Shelley Miyamoto, MD

10:30-10:40 am   Coffee Break

10:40-12:30 pm   Noncompaction Cardiomyopathy
  Session Leaders: Melanie Everitt, MD, Brian Feingold, MD, John Lynn Jefferies, MD, PhD
  • Spectrum of phenotypes of ventricular noncompaction in children.
    Jeff Towbin, MD
• Spectrum of phenotype of ventricular noncompaction in adults.
  Eloisa Arbustini, MD

• Combined Q&A
  Jeff Towbin, MD, Eloisa Arbustini, MD

• Molecular and histopathology of ventricular noncompaction.
  Weinian Shou, PhD

• The role of imaging in diagnosis and evaluation of noncompaction.
  Carolyn Taylor, MD

• Combined Q&A
  Weinian Shou, PhD, Carolyn Taylor, MD

• Case presentations:
  o Isolated ventricular noncompaction.
    Ashwin Lal, MD
  o CHD with ventricular noncompaction.
    Thomas Ryan, MD

• Moderated Panel Discussion
  o Moderator
    Brian Feingold, MD
  o Panel
    John Lynn Jefferies, MD, MPH, Jeff Towbin, MD,
    Eloisa Arbustini, MD, Carolyn Taylor, MD, Weinian Shou, PhD

12:30-1:15 pm  Lunch

1:15-3:15 pm  Arrhythmogenic Cardiomyopathy
Session Leaders: Jeff Towbin, MD, Teresa Lee, MD
• Clinical and genetic features of arrhythmogenic cardiomyopathy: the heart failure perspective.
  Luisa Mestroni, MD
• Clinical and genetic features of arrhythmogenic cardiomyopathy: the electrophysiology perspective
  Dominic Abrams, MD
• Pathophysiology of arrhythmogenic cardiomyopathy and protein/pathway targeted therapy
  Jeffrey Saffitz, MD, PhD
• Gene based diagnostics and therapeutics
  Teresa Lee, MD
• Diagnostic barriers
  Pamela Woodard, MD
• Treatment barriers and exercise guidelines
  Joseph Rossano, MD
• Next steps to achieving better outcomes
  John Lynn Jefferies, MD, MPH
• General discussion and summary

3:15-4:00 pm  Future Directions for the Pediatric Cardiomyopathy Community/Conference Wrap Up
              Steven Colan, MD

4:00 pm  Meeting Adjourns